| Dylan E Weishaar, DDS | |
|
865 Oilfield Ave, Shelby, MT 59474-2702 | |
| (406) 434-3142 | |
| (406) 434-3143 |
| Full Name | Dylan E Weishaar |
|---|---|
| Gender | Male |
| Speciality | Dentist - General Practice |
| Location | 865 Oilfield Ave, Shelby, Montana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093244212 | NPI | - | NPPES |
| 13446 | Other | MT | MONTANA LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 13446 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dylan E Weishaar, DDS Po Box 990, Shelby, MT 59474-0990 Ph: (406) 434-3110 | Dylan E Weishaar, DDS 865 Oilfield Ave, Shelby, MT 59474-2702 Ph: (406) 434-3142 |
News Archive
ZIOPHARM Oncology, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for Application Serial No. 11/257,766 entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to compounds, pharmaceutical compositions, and lyophilisates. These claims cover the Company's proprietary palifosfamide composition (ZIO-201 or ZymafosTM). The Company has recently reported positive randomized Phase II sarcoma interim data for intravenous palifosfamide at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) on November 6, 2009 and expects, following U.S. Food and Drug Administration (FDA) review, to initiate a registration trial the first half of 2010.
Scientists at the Salk Institute have discovered that the role of neurons - which are responsible for specific tasks in the brain - is much more flexible than previously believed.
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.
A new treatment using leukemia patients' own infection-fighting cells appears to protect them from infections and cancer recurrence following treatment with fludarabine-based chemotherapy, according to new research from the Perelman School of Medicine at the University of Pennsylvania.
AltheaDx, Inc. today announced the formation of a strategic partnership with Compendia Bioscience to combine their respective core capabilities in assay development, validation and bioinformatics. The two companies will jointly create novel products and services focused on cancer biomarker discovery and subsequent development of tests that predict patient outcomes in clinical trials.
› Verified 6 days ago
Dr. John Patrick Moore, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 865 Oilfield Ave, Shelby, MT 59474 Phone: 406-434-5146 Fax: 406-434-5147 | |
Dr. Bryan Drew Haight, D.D.S. Dentist Medicare: Medicare Enrolled Practice Location: 865 Oilfield Ave, Suite 3, Shelby, MT 59474 Phone: 406-434-7086 | |
Dr. Scott Allen Luly, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 50 Crossroads Drive, Shelby, MT 59474 Phone: 406-470-4111 | |
Gregory Trandon Lee Jefferson, Dentist Medicare: Not Enrolled in Medicare Practice Location: 865 Oilfield Ave, Shelby, MT 59474 Phone: 406-434-3142 |